|
|
|||||||||||||||||||||||||||
|
Eterna Therapeutics Inc (BTX) Brooklyn ImmunoTherapeutics is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Co. is seeking to develop IRX-2, a cytokine-based therapy, to treat patients with cancer. Co. also is exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using gene-editing and cell therapy technology through a license with Factor Bioscience Limited and through its subsidairies, Novellus, Inc. and Novellus, Ltd.
|
|
|||||||||||||||||||||||||||
Free BTX Email Alerts:
Eterna Therapeutics Inc (BTX) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.